Status:
TERMINATED
Feasibility of Automated Insulin Delivery With an Interoperable Algorithm Using an Alternative Insulin Pump
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
DexCom, Inc.
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical study assesses the feasibility of implementing the inControl automated insulin delivery algorithm with Dexcom continuous glucose monitoring and a compatible insulin pump in adults with t...
Detailed Description
Self-management of type 1 diabetes is challenging, efforts to optimise time spent in the target range can result in hypo- and hyperglycaemia. Structured education, glucose monitoring and advances in i...
Eligibility Criteria
Inclusion
- Aged 18 years of age or older
- Type 1 diabetes confirmed on the basis of clinical features
- Type 1 diabetes for greater than 1 year
- On an intensified insulin regimen with multiple dose injection or insulin pump for \> 3 months
- HbA1c \>7.5% (58mmol/mol) (or %TIR 3.9-10mmol/L \<52% for participants already using a continuous glucose sensor)
Exclusion
- Total daily insulin dose greater than 100 units
- Weight greater than 140kg
- Pregnant or planning pregnancy
- Have active malignancy or under investigation for malignancy
- Severe visual impairment
- Reduced manual dexterity
- Use of any automated insulin delivery system
- Unable to participate due to other factors, as assessed by the Chief Investigator
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2025
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT05299177
Start Date
April 1 2022
End Date
August 31 2025
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College London, Imperial College Healthcare NHS Trust
London, United Kingdom, W2 1PG